Abbott strong as it prepares for spin-out | InPharm

As Abbott begins to prepare for a spin out, they seem to be doing well despite an expected global economic slow down.

Sales of its anti-inflammatory blockbuster Humira rose 21% over the year to $7.93 billion, including growth of nearly 16% in the final quarter.